Vistin Pharma ASA
18.60
NOK
0.00
(0.00%)
ISIN
NO0010734122
Return %
Stock
S&P 500
1Y
-18.78
14.20
3Y
-11.43
81.12
5Y
-8.60
68.34
Capital Structure
NOK
•
in mil. unless spec.Working Capital
NOK
•
in mil. unless spec.Growth Rates
NOK
•
in mil. unless spec.Quarterly Revenue
NOK
•
in mil. unless spec.Quarterly Earnings Per Share
NOK
•
in mil. unless spec.Quarterly Dividends Per Share
NOK
•
in mil. unless spec.Company Description
- CEO
- Magnus Tolleshaug
- Full Time Employees
- 77
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Oslo Norway
- IPO Date
- Jun 10, 2015
- Website
- vistin.com
- Similar Companies
- Business
- Vistin Pharma ASA is a Norway-based specialty pharmaceutical company primarily engaged in the development, manufacture, and commercial supply of high-purity active pharmaceutical ingredients (APIs) and direct compressible granules for the global diabetes healthcare sector. The company operates within the pharmaceutical ingredients industry, specializing in Metformin Hydrochloride (HCl), a leading first-line oral therapeutic agent for the treatment and management of Type 2 diabetes. Its core product and service portfolio comprises Metformin Hydrochloride crystalline API powders compliant with major international pharmacopoeias, including the European Pharmacopoeia (Ph.Eur.), United States Pharmacopeia (USP), and Japanese Pharmacopoeia (JP); Metformin Direct Compressible (DC) granules, including 95% and 92.6% formulations pre-compounded with excipients and lubricants such as magnesium stearate to streamline solid oral dosage tablet compression; custom particle size customization and tailored granulation blends; and comprehensive regulatory compliance and quality documentation support, including United States Drug Master Files (US DMF), European Certificates of Suitability (CEP), and regulatory certifications from authorities such as the US Food and Drug Administration (FDA), the Norwegian Medical Products Agency (DMP), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and the Brazilian Health Regulatory Agency (ANVISA). Vistin Pharma serves a business-to-business customer base of multinational pharmaceutical enterprises, generic drug manufacturers, and contract development and manufacturing organizations (CDMOs), exporting its products to pharmaceutical formulators in over 100 countries across Europe, North America, Latin America, and the Asia-Pacific region. Founded in 2015 following its spin-off from Weifa ASA, with manufacturing roots dating to 1940 under Weiders Farmasøytiske, the company is headquartered in Oslo, Norway, and conducts manufacturing at its automated, cGMP-certified production facility located in Kragerø, Norway. In recent developments, Vistin Pharma completed the commercial ramp-up of a multi-million NOK expansion project at its Kragerø manufacturing facility, doubling its total annual production capacity to approximately 7,000 metric tonnes through the integration of a second production line; expanded its commercial delivery of high-margin Direct Compressible Metformin formulations to capture increasing global demand for ready-to-compress excipient-drug blends; initiated strategic infrastructure and distillation unit modernizations to optimize plant reliability and energy efficiency; and achieved record revenue and operating earnings driven by expanded capacity utilization and market share gains across core international export territories.